Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

NMRA

Neumora Therapeutics Inc.

May 02 • 09:36AM ET

9.23

Dollar change +0.13
Percentage change 1.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IWM SBIO VTWO SCHA IWN IWO ONEQ BBSC SMLF

Index	RUT	P/E	-	EPS (ttm)	-1.52	Insider Own	66.63%	Shs Outstand	158.83M	Perf Week	1.86%
Market Cap	1.47B	Forward P/E	-	EPS next Y	-1.63	Insider Trans	0.51%	Shs Float	53.21M	Perf Month	-30.61%
Income	-235.93M	PEG	-	EPS next Q	-0.34	Inst Own	14.94%	Short Float	11.03%	Perf Quarter	-39.48%
Sales	0.00M	P/S	-	EPS this Y	58.57%	Inst Trans	-	Short Ratio	10.10	Perf Half Y	-15.49%
Book/sh	2.95	P/B	3.12	EPS next Y	-8.23%	ROA	-51.15%	Short Interest	5.87M	Perf Year	-
Cash/sh	2.85	P/C	3.24	EPS next 5Y	-	ROE	-54.49%	52W Range	8.82 - 21.00	Perf YTD	-45.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-50.10%	52W High	-56.05%	Beta	-
Dividend TTM	-	Quick Ratio	19.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	4.63%	ATR (14)	0.83
Dividend Ex-Date	-	Current Ratio	19.05	EPS Y/Y TTM	-76.42%	Oper. Margin	0.00%	RSI (14)	28.07	Volatility	6.76% 7.42%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	24.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-269.65%	Payout	-	Rel Volume	13.25	Prev Close	9.10
Sales Surprise	-	EPS Surprise	-28.81%	Sales Q/Q	-	Earnings	Mar 07 BMO	Avg Volume	581.31K	Price	9.23
SMA20	-19.42%	SMA50	-34.82%	SMA200	-32.71%	Trades		Volume	497,632	Change	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	Loading…
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
07:00AM	Loading…
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:54 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:54 PM
Burow Kristina	Director	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:55 PM
Burow Kristina	Director	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:00 PM
Burow Kristina	Director	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:01 PM
Burow Kristina	Director	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:00 PM
Burow Kristina	Director	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 06:59 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 06:59 PM
Burow Kristina	Director	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 07:00 PM
Burow Kristina	Director	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 06:59 PM
Burow Kristina	Director	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:53 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:53 PM
Burow Kristina	Director	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:18 PM
Burow Kristina	Director	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:19 PM
Burow Kristina	Director	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:18 PM
Burow Kristina	Director	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:37 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:38 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:38 PM
Burow Kristina	Director	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:37 PM
AMGEN INC	10% Owner	Sep 19 '23	Buy	17.00	1,764,705	29,999,985	35,368,653	Sep 19 07:52 PM
Burow Kristina	Director	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:23 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:16 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:15 AM
Gosebruch Henry O	President & CEO	Sep 19 '23	Buy	12.62	15,000	189,370	15,000	Sep 19 09:47 PM

Open in Screener

SLRN

Acelyrin Inc

May 02 • 09:36AM ET

4.27

Dollar change +0.02
Percentage change 0.47	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBK IWM VXF IBB VTWO IWN IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	37.98%	Shs Outstand	97.87M	Perf Week	0.71%
Market Cap	422.35M	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-0.10%	Shs Float	61.35M	Perf Month	-35.60%
Income	-381.64M	PEG	-	EPS next Q	-0.96	Inst Own	72.82%	Short Float	12.79%	Perf Quarter	-47.54%
Sales	0.00M	P/S	-	EPS this Y	24.27%	Inst Trans	-	Short Ratio	6.31	Perf Half Y	-58.08%
Book/sh	6.71	P/B	0.64	EPS next Y	-15.86%	ROA	-	Short Interest	7.85M	Perf Year	-
Cash/sh	7.29	P/C	0.59	EPS next 5Y	-	ROE	-	52W Range	4.14 - 29.88	Perf YTD	-42.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.04%	52W High	-85.71%	Beta	2.38
Dividend TTM	-	Quick Ratio	8.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.14%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	8.65	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	23.39	Volatility	5.57% 6.21%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	31.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-526.06%	Payout	-	Rel Volume	0.31	Prev Close	4.25
Sales Surprise	-	EPS Surprise	551.50%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	1.24M	Price	4.27
SMA20	-16.27%	SMA50	-35.93%	SMA200	-62.17%	Trades		Volume	25,279	Change	0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
07:00AM	Loading…
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire)
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
04:30PM	Loading…
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire)
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	Loading…
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com)
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM
Westlake BioPartners Fund II,	10% Owner	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:16 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:13 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	60,000	1,080,000	60,000	May 11 09:13 PM
Gosebruch Henry O	Director	May 09 '23	Buy	18.00	50,000	900,000	50,000	May 11 09:06 PM
Svoronos Dawn	Director	May 09 '23	Buy	18.00	15,000	270,000	15,000	May 11 09:11 PM
Peloso Paul	Chief Medical Officer	May 09 '23	Buy	18.00	6,000	108,000	6,000	May 11 08:54 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	5,556	100,008	5,556	May 11 08:51 PM
Kim Mina	Chief Legal & Admin. Officer	May 09 '23	Buy	18.00	5,000	90,000	5,000	May 11 08:58 PM
Becker Daniel J.	Director	May 09 '23	Buy	18.00	3,000	54,000	3,000	May 11 09:02 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	1,750	31,500	875	May 11 08:51 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	1,000	18,000	1,000	May 11 09:00 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	26	468	26	May 11 09:00 PM

Open in Screener

ABBV

Abbvie Inc

May 02 • 09:36AM ET

161.13

Dollar change -0.59
Percentage change -0.36	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO IVV VTV SCHD VIG VYM VHT IWF DGRO

Index	S&P 500	P/E	47.90	EPS (ttm)	3.36	Insider Own	0.11%	Shs Outstand	1.77B	Perf Week	-3.68%
Market Cap	285.30B	Forward P/E	13.34	EPS next Y	12.08	Insider Trans	-19.17%	Shs Float	1.77B	Perf Month	-9.14%
Income	5.96B	PEG	7.55	EPS next Q	3.03	Inst Own	71.57%	Short Float	0.77%	Perf Quarter	-3.85%
Sales	54.40B	P/S	5.24	EPS this Y	1.11%	Inst Trans	0.10%	Short Ratio	2.35	Perf Half Y	14.13%
Book/sh	5.87	P/B	27.47	EPS next Y	7.54%	ROA	3.52%	Short Interest	13.54M	Perf Year	6.27%
Cash/sh	7.24	P/C	22.26	EPS next 5Y	6.34%	ROE	34.90%	52W Range	130.96 - 182.89	Perf YTD	3.97%
Dividend Est.	6.25 (3.88%)	P/FCF	12.95	EPS past 5Y	-5.77%	ROI	9.42%	52W High	-11.90%	Beta	0.59
Dividend TTM	6.06 (3.76%)	Quick Ratio	0.76	Sales past 5Y	11.76%	Gross Margin	84.65%	52W Low	23.04%	ATR (14)	3.41
Dividend Ex-Date	Apr 12, 2024	Current Ratio	0.87	EPS Y/Y TTM	-59.03%	Oper. Margin	32.72%	RSI (14)	36.38	Volatility	2.81% 2.24%
Employees	50000	Debt/Eq	5.80	Sales Y/Y TTM	-4.12%	Profit Margin	10.96%	Recom	2.00	Target Price	183.47
Option/Short	Yes / Yes	LT Debt/Eq	5.11	EPS Q/Q	501.32%	Payout	220.33%	Rel Volume	0.05	Prev Close	161.72
Sales Surprise	3.19%	EPS Surprise	2.24%	Sales Q/Q	0.70%	Earnings	Apr 26 BMO	Avg Volume	5.77M	Price	161.13
SMA20	-2.76%	SMA50	-7.19%	SMA200	2.49%	Trades		Volume	19,484	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-10-23	Upgrade	SVB Securities	Underperform → Market Perform	$135 → $153
Nov-18-22	Initiated	Credit Suisse	Outperform	$170
Nov-08-22	Downgrade	Societe Generale	Buy → Hold
Aug-01-22	Downgrade	Atlantic Equities	Overweight → Neutral	$178 → $162
May-23-22	Initiated	SVB Leerink	Underperform	$140
May-06-22	Downgrade	Daiwa Securities	Outperform → Neutral	$150
Apr-06-22	Resumed	Morgan Stanley	Overweight	$192
Feb-28-22	Downgrade	UBS	Buy → Neutral	$129 → $147

Show Previous Ratings

Today 03:01AM	The top pharmaceutical companies by R&D expenditure (Pharmaceutical Technology)
May-01-24 01:46PM	CVS stresses 'margins over membership' to offset Medicare pressure (Yahoo Finance)
01:46PM	CVS stock plunges after earnings numbers one analyst 'did not even believe' (Yahoo Finance)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Apr-30-24 01:50PM	7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns (InvestorPlace)
12:02PM	Loading…
12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
11:45AM	AbbVie (ABBV) Could Be a Great Choice (Zacks)
08:38AM	AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	AbbVie Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
06:32AM	Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing (InvestorPlace)
Apr-29-24 04:06PM	AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales (Investor's Business Daily)
11:24AM	BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating (MT Newswires)
08:37AM	Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 (MT Newswires)
08:24AM	Barclays Adjusts Price Target on AbbVie to $187 From $195 (MT Newswires)
Apr-28-24 06:54PM	Dividend Stock Portfolio For Income: Top 15 Stocks (Insider Monkey)
06:49PM	Loading…
06:49PM	What is an Annuity for Retirement? 15 Dividend Stocks to Buy Instead (Insider Monkey)
07:17AM	12 Under-the-Radar High Dividend Stocks to Invest in Now (Insider Monkey)
04:20AM	Better Dividend Stock: AbbVie or Johnson & Johnson? (Motley Fool)
Apr-27-24 07:15AM	3 Dividend Stocks to Buy and Hold for the Next Decade (Motley Fool)
03:07AM	AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ... (GuruFocus.com)
01:24AM	Q1 2024 AbbVie Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-26-24 05:31PM	Abbvie stock falls amid growing biosimilar competition (Yahoo Finance Video)
04:08PM	AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That (Investor's Business Daily)
04:07PM	Why AbbVie Stock Stumbled Today Despite the Earnings Beat (Motley Fool)
03:15PM	AbbVie (ABBV) Q1 2024 Earnings Call Transcript (Motley Fool)
03:04PM	AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump (Investopedia)
01:30PM	Microsoft, Alphabet earnings fuel stock rally: Yahoo Finance (Yahoo Finance Video)
01:04PM	Analyst Report: AbbVie Inc. (Morningstar Research)
12:10PM	AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View (Zacks)
11:52AM	ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:02AM	Loading…
11:02AM	Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks (Pharmaceutical Technology)
11:02AM	AbbVie's newer drugs are offsetting losses of the world's once best-selling medication (Quartz)
10:30AM	AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:58AM	AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop (Barrons.com)
09:16AM	Sector Update: Health Care Stocks Mixed Premarket Friday (MT Newswires)
09:11AM	AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges (GuruFocus.com)
09:03AM	AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title (Investor's Business Daily)
08:45AM	AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:07AM	AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update (RTT News)
08:06AM	AbbVie's Q1 Adjusted Earnings Fall, Net Revenue Rises; 2024 Adjusted Profit Outlook Lifted (MT Newswires)
07:44AM	AbbVie lifts profit forecast after Skyrizi sales beat expectations (Reuters)
07:43AM	AbbVie: Q1 Earnings Snapshot (Associated Press Finance)
07:36AM	AbbVie raises annual profit forecast on strong Skyrizi sales (Reuters)
07:35AM	AbbVie Reports First-Quarter 2024 Financial Results (PR Newswire)
07:00AM	PCE reading, Microsoft, Alphabet jump on earnings: Yahoo Finance (Yahoo Finance Video)
Apr-25-24 04:48PM	Cigna to offer Humira rivals with $0 copay at specialty pharmacy (Reuters)
10:58AM	AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint (MT Newswires)
08:44AM	UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study (Reuters)
08:15AM	REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study (Reuters)
08:00AM	New Data Show RINVOQ (upadacitinib) Demonstrated Superiority Versus DUPIXENT (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study (PR Newswire)
Apr-23-24 03:09PM	Nvidia will soar 21% to $1,000 as its new AI chip slams would-be rivals, Morgan Stanley says. Its among 10 stocks set to surge (Fortune)
12:38PM	UPDATE 1-US CDC warns of harmful reactions to fake Botox injections (Reuters)
12:14PM	US CDC warns of harmful reactions to fake Botox injections (Reuters)
09:15AM	Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
08:00AM	Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands (PR Newswire)
Apr-22-24 12:56PM	AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? (Zacks)
09:47AM	Buying the Dip in These 3 Undervalued Dividend Stocks (Motley Fool)
Apr-21-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-19-24 04:11PM	The Bad News Heading Into AbbVie's First-Quarter Earnings Report (Investor's Business Daily)
10:00AM	Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline (Zacks)
Apr-18-24 03:44PM	Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study (Benzinga)
12:18PM	Heard on the Street: AbbVies Bet on a Neuroscience Drug Maker Just Got Better (The Wall Street Journal)
08:31AM	Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients With Giant Cell Arteritis (PR Newswire)
06:30AM	Cerevel, in major surprise, finds success in late-stage Parkinsons study (BioPharma Dive)
Apr-17-24 05:45PM	AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Apr-16-24 10:21AM	UPDATE 1-US FDA warns of harmful reactions to fake Botox injections (Reuters)
10:01AM	US FDA says counterfeit versions of Botox found in multiple states (Reuters)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:00AM	Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc (GuruFocus.com)
03:06AM	15 Best Monthly Dividend Stocks To Buy Right Now (Insider Monkey)
03:02AM	12 Best Dividend Stocks with High Upside Potential (Insider Monkey)
Apr-15-24 07:57AM	Roche reports survival data for new dual-acting lymphoma drug (BioPharma Dive)
07:43AM	16 Best Dividend Stocks of All Time (Insider Monkey)
Apr-14-24 01:23AM	Is AbbVie a Millionaire Maker? (Motley Fool)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
Apr-12-24 04:19PM	What's Going On AbbVie Stock On Friday? (Benzinga)
07:30AM	AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA) for Preventive Treatment of Migraine (PR Newswire)
Apr-11-24 05:45PM	AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors (Zacks)
07:02AM	AbbVie Inc's Dividend Analysis (GuruFocus.com)
Apr-10-24 10:53AM	AbbVie Is One of the Best Positioned Large Cap Stocks (Barrons.com)
Apr-09-24 08:00AM	SkinMedica Empowers Clear Skin Confidence with a New, Modern Approach to Acne (PR Newswire)
07:13AM	10 Unstoppable Dividend Stocks To Buy (Insider Monkey)
04:21AM	3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade (Motley Fool)
Apr-08-24 05:50PM	Here's Why AbbVie (ABBV) Fell More Than Broader Market (Zacks)
09:19AM	CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-06-24 06:49AM	3 No-Brainer Dividend Stocks to Buy in April (Motley Fool)
Apr-05-24 05:45PM	CollPlant Biotechnologies Ltd (CLGN) Q4 2023 Earnings Call Transcript Highlights: A Year of ... (GuruFocus.com)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	Boehringer Ingelheim to lay off staff amid biosimilar challenges (BioPharma Dive)
06:39AM	UPDATE 1-Boehringer to lay off salespeople as Humira biosimilar sales lag (Reuters)
Apr-04-24 06:52PM	Boehringer to lay off salespeople as Humira biosimilar sales lag (Reuters) -5.32%
08:00AM	AbbVie to Host First-Quarter 2024 Earnings Conference Call (PR Newswire)
Apr-03-24 08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
08:30AM	Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting (PR Newswire)
Apr-02-24 12:41PM	US takes next step in Medicare drug price negotiations with pharma companies (Reuters)
10:28AM	NEXGEL, Inc. (NASDAQ:NXGL) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	AbbVie Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
03:36AM	Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation (Motley Fool)
Apr-01-24 05:45PM	AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
07:50AM	NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year (GlobeNewswire)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Mar 20 '24	Sale	176.30	21,082	3,716,757	55,903	Mar 22 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Option Exercise	61.36	26,110	1,602,110	119,890	Mar 20 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Sale	178.79	58,949	10,539,508	60,941	Mar 20 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Option Exercise	61.36	45,700	2,804,152	89,517	Mar 05 05:30 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Sale	177.27	75,680	13,415,503	13,837	Mar 05 05:30 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Option Exercise	58.30	21,560	1,257,012	167,524	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Sale	176.45	68,879	12,153,957	98,645	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 29 '24	Sale	177.39	9,891	1,754,555	10,397	Mar 01 05:50 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 29 '24	Sale	176.65	5,144	908,688	6,983	Mar 01 05:50 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Feb 28 '24	Sale	177.27	138,616	24,572,458	519,099	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Option Exercise	137.36	13,753	1,889,115	41,926	Feb 27 05:10 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Option Exercise	61.36	14,140	867,630	41,205	Mar 01 05:50 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Sale	177.44	14,140	2,509,002	27,065	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Sale	177.51	13,753	2,441,295	28,173	Feb 27 05:10 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Option Exercise	58.88	52,870	3,112,986	296,814	Feb 23 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Sale	173.71	52,870	9,184,048	243,944	Feb 23 05:00 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Dec 26 '23	Sale	154.72	2,912	450,545	55,903	Dec 28 05:00 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Aug 01 '23	Sale	148.58	60,000	8,914,800	565,294	Aug 02 05:07 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Jul 31 '23	Sale	149.15	18,500	2,759,275	625,294	Aug 02 05:07 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

NMRA

Neumora Therapeutics Inc.

SLRN

Acelyrin Inc

ABBV

Abbvie Inc

Upgrade your FINVIZ experience